Inovio Pharmaceuticals competitors

Inovio Pharmaceuticals's competitors include Anthera Pharmaceuticals, Vertex Pharmaceuticals, MyoKardia and Athersys
Add company...
Inovio Pharmaceuticals
Inovio Pharmaceuticals is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid immunotherapies and vaccines.
Anthera Pharmaceuticals
Anthera Pharmaceuticals is focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Founding Date
Founding Date
1979
Founding Date
2004
Founding Date
1989
Founding Date
2012
Founding Date
1995
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Blue Bell, US HQ
San Diego, US
San Diego, US
Locations
Hayward, US HQ
Locations
Boston, US HQ
Locations
South San Francisco, US HQ
Locations
Cleveland, US HQ
Canton, US
Employees
Employees
239
Employees
33
Employees
2,3007% increase
Employees
1024% increase
Employees
60
Valuation ($)
Valuation ($)
385.7 m
Valuation ($)
7.3 m
Valuation ($)
40.6 b
Valuation ($)
1.7 b
Valuation ($)
281.4 m
Facebook likes
Facebook likes
265
Facebook likes
58
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
475
Twitter followers
Twitter followers
7 k
Twitter followers
343
Twitter followers
32.9 k
Twitter followers
387
Twitter followers
953

Financial

Revenue (est.)
Revenue (est.)
$42.2m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$2.5b (FY, 2017)
Revenue (est.)
$22.5m (FY, 2017)
Revenue (est.)
$3.7m (FY, 2017)
Net income
Net income
($88.2m) (FY, 2017)
Net income
($26.9m) (FY, 2017)
Net income
$91.6m (FY, 2017)
Net income
($46m) (FY, 2017)
Net income
N/A

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
4 (FY, 2017)
Patents (US)
21 (FY, 2016)
Patents Issued
Patents Issued
620 (FY, 2016)
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
200 (FY, 2016)

Funding

Total funding raised
Total funding raised
$ 63.3m
Total funding raised
$ 31.5m
Total funding raised
$ 2.4m
Total funding raised
$ 98m
Total funding raised
$ 9m
For sources of this data, please see the company profileDownload Excel

View company profiles

Anthera Pharmaceuticals
HQ
Hayward, US
Employees
33

Anthera Pharmaceuticals is focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.

View company
Vertex Pharmaceuticals
HQ
Boston, US
Employees
2,300↑ 7% increase

Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.

View company
MyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Athersys
HQ
Cleveland, US
Employees
60

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company